Biosite's Triage BNP assay
This article was originally published in The Gray Sheet
Premarket approval application for congestive heart failure test will be reviewed by FDA's Clinical Chemistry and Clinical Toxicology Devices Panel on March 24. The blood-based Triage B-type natriuretic peptide (BNP) is intended to provide in 20 minutes results that will serve as an aid in diagnosing CHF, the firm maintains
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.